---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-012718"
form_type: "8-K"
ticker: "MTNB"
cik: "0001582554"
company_name: "Matinas BioPharma Holdings, Inc."
filed_at: "2023-04-18T23:59:59+00:00"
generated_at: "2026-06-17T00:45:22.664288+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Matinas BioPharma: compassionate use patient complete resolution of rare fungal infection with MAT2203; Phase 3 planned

## Summary
- Patient treated with MAT2203 achieved complete clinical resolution of R. mucilaginosa infection after 6 months and regained use of foot.
- MAT2203 was well-tolerated with no renal adverse effects; patient's renal function improved and remained at baseline.
- Prior IV-amphotericin B was discontinued due to electrolyte abnormalities and toxicities; MAT2203 allowed outpatient monitoring.
- Company in final stages of planning Phase 3 program for MAT2203 with FDA.

## SEC filing metadata
- accession: 0001493152-23-012718
- form_type: 8-K
- ticker: MTNB
- cik: 0001582554
- company_name: Matinas BioPharma Holdings, Inc.
- filed_at: 2023-04-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582554/000149315223012718/0001493152-23-012718-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582554/000149315223012718/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-012718
- JSON: https://secwatch.observer/filing/0001493152-23-012718.json
- Plain text: https://secwatch.observer/filing/0001493152-23-012718.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.